Skip to main content

Estrella Immunopharma, Inc.

ESLAW
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001844417

No open-market purchases or sales by Estrella Immunopharma, Inc. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $249.2K in total; no superinvestor holds it.

Other share classesESLA

Q4 2023 vs. Q3 2023

How the institutions holding Estrella Immunopharma, Inc. changed between Q3 2023 and Q4 2023.

All holders in Q4 2023All holders in Q3 2023

13F holders of ESLAW: Q3 2023 compared with Q4 2023
MeasureQ3 2023Q4 2023Change
Holders114+13
Shares11.8K646.0K+634.2K (+5,372.5%)
Value$1.75K$27.9K+$26.1K (+1,496.0%)

New holders (13)

Institutions that held Estrella Immunopharma, Inc. at the end of Q4 2023 but not at the end of Q3 2023.

Institutions new to ESLAW in Q4 2023
InstitutionSharesValue% of portfolio
Highbridge Capital Management LLC–$12.4K0.00%
D. E. Shaw & Co., Inc.87,500$4.26K0.00%
SkyView Investment Advisors, LLC62,500$2.00K0.00%
Walleye Capital LLC66,112$1.98K0.00%
Yakira Capital Management, Inc.46,485$1.40K0.00%
Whitebox Advisors LLC45,476$1.36K0.00%
Walleye Trading LLC37,188$1.12K0.00%
Clear Street LLC28,591$8580.00%
Cowen and Company, LLC28,597$8570.00%
Susquehanna International Group, LLP22,486$6750.00%
Landscape Capital Management, L.L.C.13,682$4100.00%
Wolverine Asset Management LLC5,703$1710.00%
Boothbay Fund Management, LLC189,899––

Sold out (0)

Institutions that held Estrella Immunopharma, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.

None.